Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

News SummaryMost relevantAll newsSector news 

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 07:01pm CET
   By Peter Loftus 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
12/06 BRISTOL MYERS SQUIBB : Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimu..
12/05 BRISTOL MYERS SQUIBB : Encouraging Survival Observed With Opdivo (nivolumab) Plu..
12/01 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Yield New Information a..
12/01 BRISTOL MYERS SQUIBB : Trademark Application for "NIVDIREC" Filed
12/01 BRISTOL MYERS SQUIBB : Trademark Application for "IMMVIVUR" Filed
12/01 BRISTOL MYERS SQUIBB : European Commission Approves Bristol-Myers Squibb's Opdiv..
12/01 BRISTOL MYERS SQUIBB : Studies Conducted at Bristol-Myers Squibb on Alcohols Rec..
12/01 BRISTOL MYERS SQUIBB : New Findings from Bristol-Myers Squibb Update Understandi..
12/01 BRISTOL MYERS SQUIBB : New Hepatitis C Virus Study Findings Reported from Bristo..
12/01 BRISTOL MYERS SQUIBB : Trademark Application for "AWAKEN" Filed
More news
Sector news : Pharmaceuticals - NEC
08:44p MYLAN : EpiPen maker Mylan to restructure, cut workforce
07:47pDJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
07:16pDJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
07:15pDJABBOTT LABORATORIES : Seeks to Terminate Alere Deal
05:34pDJMARKET SNAPSHOT : Dow, S&P 500 Set Intraday Records, But Health-care Slumps On T..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:50p ET TU, DONALD? DRUGS DIVE : What's Going On, And What's Next
01:30p Bristol-Myers Squibb's (BMY) Management Presents at Citi 2016 Global Healthca..
12/06 Nektar Therapeutics Is Attractive Ahead Of Multiple Catalysts
12/06 What Could Pfizer Do With Cash From A Tax Holiday
12/04 December 2016's 10 Worst CCC Stocks At Various Market Caps
Financials ($)
Sales 2016 19 331 M
EBIT 2016 5 346 M
Net income 2016 4 615 M
Debt 2016 160 M
Yield 2016 2,79%
P/E ratio 2016 20,41
P/E ratio 2017 19,77
EV / Sales 2016 4,85x
EV / Sales 2017 4,65x
Capitalization 93 639 M
More Financials
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 62,1 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.09%304 863
PFIZER INC.-2.23%191 517
ROCHE HOLDING LTD.-19.65%190 397
NOVARTIS AG-20.79%180 387
MERCK & CO., INC.14.12%166 200
More Results